Trellus Health Plc. Signs an Agreement to Provide an Inflammatory Bowel Disease Demonstration Programme for the Mount Sinai Health System Employee Health Plan
September 17, 2021 at 08:00 am EDT
Share
Trellus Health plc announced that it has signed an agreement to provide an Inflammatory Bowel Disease demonstration programme for the Mount Sinai Health System ("Mount Sinai") employee health plan (the "Agreement"), one of the largest self-insured employer health plans in New York State. As outlined in the Company's Admission Document, Trellus Health intends to begin generating revenue in the current year through a number of demonstration projects, potentially involving several hundred patients in aggregate. This initial Agreement will assess feasibility, engagement and satisfaction of the Company's digital chronic condition management solution for Mount Sinai's non-union employees, eligible dependents and their treating physicians. Under the Agreement, Trellus Health will recruit, assess and engage eligible IBD patients, with a targeted total enrolment of 25 patients. Following enrolment, the demonstration programme will coordinate six months of active care management followed by a final programme report, expected to be available within 30 days of programme completion. This initial demonstration programme is expected to commence before the end of 2021 with conclusions from the final programme report expected in 2022. The solutions deployed in this and other planned demonstration programmes will utilise the scientifically validated patent-pending GRITTTM resilience assessment and personalized care management methodology and a proprietary technology platform called TrellusElevate™, to coordinate and deliver personalised clinical and behavioural care remotely via telehealth. The Company expects to scale its initial demonstration projects into longer-term and broader-ranging contracts based on the achievement of successful IBD patient and physician engagement and satisfaction rates. The Company continues to engage with prospective partners and customers on additional demonstration programmes. These are being designed to illustrate the potential health economics and return on investment to payers of the Company's digital chronic condition management solutions and generate data to drive demand for greater adoption, whilst simultaneously generating additional revenues for the Company. Previous studies with IBD patients demonstrated significant improvements in resilience and reductions in unplanned healthcare by utilizing the Company's proprietary methodology and resilience-driven multidisciplinary care model. The Directors estimate that chronic and mental health conditions and IBD, represent over $3 trillion and $30-50 billion in total annual costs in the US, respectively. Trellus Health is initially focused on IBD, which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions including Irritable Bowel Syndrome ("IBS"), diabetes, cancer, kidney disease, cardiac, respiratory and autoimmune conditions. The Company will utilize the GRITTTM resilience assessment and personalized care management methodology, which were validated on IBD patients at the Susan and Leonard Feinstein IBD Clinical Center at The Mount Sinai Hospital, where Crohn's disease was first identified by Dr. Burrill B. Crohn, MD in 1932. The GRITTTM resilience assessment and personalized treatment methodology described is based on technology developed by Mount Sinai faculty and licensed to Trellus Health. Mount Sinai and Mount Sinai faculty, including Marla Dubinsky, MD, and Laurie Keefer, PhD, have a financial interest in Trellus Health. Mount Sinai has representation on the Trellus Health Board of Directors.
Trellus Health plc is a United Kingdom-based digital health company. It offers a scientifically validated, personalized resilience-based self-management training program for people living with chronic conditions. It is focused on the intersection of chronic physical conditions and mental health. The Company's approach transforms chronic disease management and changes the lives of patients living with debilitating, incurable conditions, primarily focused on inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, and irritable bowel syndrome (IBS). The TrellusElevate platform is the Company's connected health platform that incorporates the Gaining Resilience Through Transitions (GRITT) methodology and learnings on resilience from clinical research and practice. Through its TrellusElevate connected care platform and companion App, the Company addresses both clinical and behavioral health together. The Company's wholly owned subsidiary is Trellus Health Inc.
Trellus Health Plc. Signs an Agreement to Provide an Inflammatory Bowel Disease Demonstration Programme for the Mount Sinai Health System Employee Health Plan